
Kateryna Babenko calls preparation for frozen transfer "the art of cryoprotocols," whose result should be "masterpieces" — a living, healthy mother and child, not merely a positive test.
She opens with an interactive vote: what does the audience choose more often — HRT or a natural cycle. Historically, both worldwide and in Ukraine, the hormone-replacement (HRT) protocol was used more: it is simple, controllable, convenient for timing, created over 30 years ago to synchronise with a donor.
However, HRT is associated with a somewhat lower live-birth rate and a higher risk of early loss than the natural cycle. The key mechanism is the absence of a corpus luteum and the vasoactive factors it produces.
Perinatal risks of the artificial cycle are higher: the risk of pre-eclampsia rises almost twofold in singleton and more in multiple pregnancy. A meta-analysis shows that using a natural cycle can prevent a share of adverse outcomes per 1,000 women.
Target groups for the long protocol are examined (premature ovarian insufficiency, fibroids, adenomyosis): large studies showed no significant advantage of the long agonist protocol over standard HRT or the natural cycle; in adenomyosis, adding aromatase inhibitors may help.
Hence the shift "from efficiency to safety": the aim is not to create a cycle artificially but to use the patient's own reproductive physiology. This brings natural and modified cycles to the fore.
Natural cycles come as "wild" ones (monitoring LH, progesterone, follicle collapse), trigger-modified (hCG fixes the day) and progesterone-modified (exogenous progesterone instead of a trigger).
The variability of the LH peak (24 to 56 hours before ovulation) and optimal transfer windows are discussed: by the data, the best results are around 160 hours from the peak/trigger, with an acceptable margin within a day.
Flexibility can be increased by using follicle diameter when assigning the trigger: classically 17-18 mm, but smaller diameters are also proposed (13-16, 16-19, 19-22), since it is the corpus luteum, not the oocyte, that is needed. The progesterone-modified cycle is promising, though the evidence base is still limited.
A separate point on changing protocol after a failure: switching from one type to another does not significantly raise the odds. It is better to choose a protocol by the patient's baseline characteristics from the start and follow it consistently. The bottom line: medicine is not only algorithms but the art of decision-making, and ART is an "art" too.
Natural, modified natural or hormone replacement cycle — what determines the choice? A comparison of endometrial preparation protocols for frozen embryo transfer, the role and monitoring of progesterone, and synchronising the implantation window with embryo transfer.
Patients arrive at the clinic already having consulted ChatGPT, and regulators are reviewing the first AI ‘doctors’. What in artificial intelligence already works in reproductive medicine — from assistant avatars to embryo assessment and stimulation personalisation? A live discussion on three levels — strategy, service and clinic — with practical cases and a panel Q&A.


A Sona-Pharm grant award for specialists in infertility treatment. Applications open on 1 February 2027. Ceremony — July 2027, Stockholm, during the ESHRE meeting.

Targeted, biomarker-guided immunotropic therapy in reproductive medicine. A lecture by Kseniia Khazhylenko at the UARM Symposium 2026.
Audio: UASubtitles: UA32 min
